PE20231066A1 - Agonistas heterociclicos de glp-1 - Google Patents
Agonistas heterociclicos de glp-1Info
- Publication number
- PE20231066A1 PE20231066A1 PE2022001553A PE2022001553A PE20231066A1 PE 20231066 A1 PE20231066 A1 PE 20231066A1 PE 2022001553 A PE2022001553 A PE 2022001553A PE 2022001553 A PE2022001553 A PE 2022001553A PE 20231066 A1 PE20231066 A1 PE 20231066A1
- Authority
- PE
- Peru
- Prior art keywords
- ring
- alkyl
- alkylene
- bond
- cycloalkyl
- Prior art date
Links
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- -1 RLa is H Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
- C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Refiere a agonistas de GLP-1 de Formula (I), o una sal o solvato farmaceuticamente aceptable de los mismos, en donde Q1, Q2, Q3, Q4 y Q5, forman parte de un anillo con enlaces simples o dobles, siempre que este sea aromatico, y se seleccionan, de acuerdo con (AA) o (BB), de N, CH, CRQA, CRQB, entre otros; R1, R2 y R3 se seleccionan de H y C1-6 alquilo y se sustituyen con 1-6 sustituyentes del grupo de halo, -OH y C1-6 alcoxi; L1 es -C(=O)-, -CH2-, -CH(C1-6 alquil)- y -S(=O)2; en L2, aa es el punto de union al anillo de Q1-Q5, L2A es un enlace o C1-10 alquileno, RLa es H, C1-6 alquilo y C(=O)(C1-6 alquilo), y n1 es 1-3; el anillo A es C6-10 arilo, C5-7 cicloalquilo, heterociclilo de 5-7 miembros o un heteroarilo de 5-10 miembros; en el anillo B, bb es el punto de union a L1., R4, R5, R6 y R7 se seleccionan de H, halo y C1-6 alquilo, R8a y R8b forman un anillo C3-15 cicloalquilo, L3 es un enlace o C1-3 alquileno y L4 es un enlace o C1-5 alquileno; y el anillo C se selecciona del grupo conformado por un heterociclilo de 3-12 miembros; C3-15 cicloalquilo; y un heteroarilo de 5-10 miembros. Tambien, refiere a una composicion farmaceutica que comprende al compuesto y un excipiente farmaceuticamente aceptable y un metodo para el tratamiento de la diabetes mellitus tipo 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020074537 | 2020-02-07 | ||
| CN2020109304 | 2020-08-14 | ||
| PCT/CN2021/075488 WO2021155841A1 (en) | 2020-02-07 | 2021-02-05 | Heterocyclic glp-1 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231066A1 true PE20231066A1 (es) | 2023-07-17 |
Family
ID=77199190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001553A PE20231066A1 (es) | 2020-02-07 | 2021-02-05 | Agonistas heterociclicos de glp-1 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11492365B2 (es) |
| EP (2) | EP4458834A3 (es) |
| JP (1) | JP2023513272A (es) |
| KR (1) | KR20220156535A (es) |
| CN (1) | CN115698003B (es) |
| AU (1) | AU2021216324B2 (es) |
| CA (1) | CA3169975A1 (es) |
| CL (1) | CL2022002105A1 (es) |
| CO (1) | CO2022011065A2 (es) |
| CR (1) | CR20220371A (es) |
| DK (1) | DK4097099T3 (es) |
| DO (1) | DOP2022000158A (es) |
| ES (1) | ES2986788T3 (es) |
| FI (1) | FI4097099T3 (es) |
| HR (1) | HRP20241159T1 (es) |
| HU (1) | HUE068174T2 (es) |
| IL (1) | IL295281A (es) |
| LT (1) | LT4097099T (es) |
| MA (1) | MA58498B1 (es) |
| MD (1) | MD4097099T2 (es) |
| MX (1) | MX2022009524A (es) |
| PE (1) | PE20231066A1 (es) |
| PH (1) | PH12022552056A1 (es) |
| PL (1) | PL4097099T3 (es) |
| PT (1) | PT4097099T (es) |
| RS (1) | RS65877B1 (es) |
| SI (1) | SI4097099T1 (es) |
| SM (1) | SMT202400344T1 (es) |
| TW (1) | TW202142538A (es) |
| WO (1) | WO2021155841A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| KR20220092909A (ko) | 2019-10-25 | 2022-07-04 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
| EP4097097B1 (en) | 2020-01-29 | 2025-01-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| TW202142538A (zh) | 2020-02-07 | 2021-11-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ－１促效劑 |
| CN116368140A (zh) * | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20240217966A1 (en) | 2021-03-24 | 2024-07-04 | Shionogi & Co., Ltd. | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| PE20240362A1 (es) | 2021-04-21 | 2024-03-04 | Gilead Sciences Inc | Compuestos moduladores del glp-ir carboxibenzimidazolicos |
| US20240366639A1 (en) * | 2021-08-12 | 2024-11-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN118215478A (zh) | 2021-09-08 | 2024-06-18 | 盐野义制药株式会社 | 用于预防和治疗与抗肥胖作用有关的疾病的药物 |
| WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
| WO2024063143A1 (ja) | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物 |
| CN116003403B (zh) * | 2022-11-20 | 2024-07-23 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑类化合物、药物组合物及其应用 |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2024153070A1 (en) * | 2023-01-17 | 2024-07-25 | Fochon Biosciences, Ltd. | Glp-1r agonists and uses thereof |
| WO2025002326A1 (zh) * | 2023-06-30 | 2025-01-02 | 正大天晴药业集团股份有限公司 | 含多稠环结构的化合物 |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| WO2025011664A1 (zh) * | 2023-07-12 | 2025-01-16 | 歌礼制药(中国)有限公司 | Glp-1r激动剂的制剂及其制备方法 |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2025015268A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Modulators of calcitonin receptor and/or amylin receptor activity |
| WO2025026270A1 (zh) * | 2023-07-28 | 2025-02-06 | 上海翰森生物医药科技有限公司 | 一种苯并含氮杂环类衍生物调节剂、其制备方法和应用 |
| WO2025026436A1 (zh) * | 2023-08-02 | 2025-02-06 | 韦恩生物科技有限公司 | 一种含氮并环化合物及其制备方法和用途 |
| WO2025045208A1 (en) * | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025057134A2 (en) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| CN117447493A (zh) * | 2023-12-25 | 2024-01-26 | 药康众拓(北京)医药科技有限公司 | 氘代吲哚嗪类化合物、药物组合物及其应用 |
| CN119176808A (zh) * | 2024-11-25 | 2024-12-24 | 山东法恩新材料科技有限公司 | 一种glp-1激动剂及其制备方法和应用 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212435B (en) | 1990-06-07 | 1996-06-28 | Sandoz Ag | Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients. |
| CZ7696A3 (en) | 1993-07-09 | 1996-04-17 | Schering Corp | Process for preparing azetidinone |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| JPH08295646A (ja) | 1995-04-26 | 1996-11-12 | Teijin Ltd | ビス（ヒドロキシエトキシフェニル）化合物の製造方法 |
| AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| US6187774B1 (en) | 1996-03-04 | 2001-02-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and pharmaceutical applications thereof |
| JP2001508446A (ja) | 1997-01-13 | 2001-06-26 | ザ ペン ステイト リサーチ ファウンデイション | キラル複素環式化合物による不斉合成および触媒作用 |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6628343B1 (en) | 1997-05-23 | 2003-09-30 | Sony Corporation | Television signal reception circuit, automatic phase shift control circuit and equal amplitude addition circuit |
| IT1292461B1 (it) | 1997-07-03 | 1999-02-08 | Great Lakes Chemical Italia | Composti fotocromatici,procedimento per la loro preparazione e loro utilizzo in materiali polimerici |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| EP1237547A2 (en) | 1999-07-09 | 2002-09-11 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| US7256201B2 (en) | 2000-12-07 | 2007-08-14 | Astrazeneca Ab | Selective estrogen receptor-β ligands |
| US6849643B2 (en) | 2000-12-08 | 2005-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| US7196095B2 (en) | 2001-06-25 | 2007-03-27 | Merck & Co., Inc. | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds |
| WO2003064617A2 (en) | 2002-01-30 | 2003-08-07 | Montana State University | Pestalotiopsis microsporia isolates and compounds derived therefrom |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| AU2003270186A1 (en) | 2002-09-17 | 2004-04-08 | Actelion Pharmaceuticals Ltd | 1-pyridin-4-yl-urea derivatives |
| TW200416029A (en) | 2002-11-01 | 2004-09-01 | Takeda Chemical Industries Ltd | Agent for preventing or treating neuropathy |
| WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| WO2004106276A1 (ja) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | 縮合環化合物 |
| US20040259179A1 (en) | 2003-05-30 | 2004-12-23 | Gerd Assmann | Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
| PL1668014T3 (pl) | 2003-09-17 | 2009-06-30 | Janssen Pharmaceutica Nv | Skondensowane związki heterocykliczne jako modulatory receptora serotoninowego |
| WO2005030740A1 (ja) | 2003-09-30 | 2005-04-07 | Takeda Pharmaceutical Company Limited | チアゾリン誘導体およびその用途 |
| JP4769082B2 (ja) | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
| KR20060135661A (ko) | 2003-12-18 | 2006-12-29 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 화합물 |
| WO2005066136A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| US7846959B2 (en) | 2004-05-07 | 2010-12-07 | Exelixis, Inc. | Raf modulators and methods of use |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| WO2005121138A2 (en) | 2004-06-03 | 2005-12-22 | Rigel Pharmaceuticals, Inc. | Heterotricyclic compounds for use as hcv inhibitors |
| US20050287100A1 (en) | 2004-06-08 | 2005-12-29 | Lebre Caroline | Cosmetic composition comprising a semi-crystalline polymer and a dispersion of polymer in fatty phase |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| BRPI0515532A (pt) | 2004-09-21 | 2008-07-29 | Athersys Inc | composto, composição farmacêutica, métodos de inibir a ligação de ligandos endógenos ao receptor de crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor de crt-2 e de preparar um composto, e, kit |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| EP1845970B1 (en) | 2005-01-31 | 2013-08-28 | Cephalon, Inc. | Tumor necrosis factor inhibitors |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| CA2614401A1 (en) | 2005-07-15 | 2007-01-25 | F. Hoffmann-La Roche Ag | Novel heteroaryl fused cyclic amines |
| WO2007013694A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | フェノキシアルカン酸化合物 |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| TW200740435A (en) | 2005-08-10 | 2007-11-01 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| US20070112012A1 (en) | 2005-11-11 | 2007-05-17 | Markus Boehringer | Carbocyclic fused cyclic amines |
| EP1986643A1 (en) | 2006-02-10 | 2008-11-05 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| CN103070854A (zh) | 2006-06-27 | 2013-05-01 | 武田药品工业株式会社 | 稠环化合物 |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| JP2009544723A (ja) | 2006-07-24 | 2009-12-17 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害剤としてのチオゾリジンジオン誘導体 |
| EP2077267A4 (en) | 2006-10-18 | 2010-04-07 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| US7652133B2 (en) | 2006-10-19 | 2010-01-26 | Takeda Pharmaceutical Company Limited | Indole compound |
| CN101573339A (zh) | 2006-11-03 | 2009-11-04 | 格兰马克药品股份有限公司 | 作为大麻素受体配体的桥接二环吲唑 |
| ATE552262T1 (de) | 2006-11-29 | 2012-04-15 | Pfizer Prod Inc | Spiroketone als inhibitoren von acetyl-coa- carboxylase |
| EP2124913A1 (en) | 2006-12-22 | 2009-12-02 | Novartis AG | 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors |
| US20100016396A1 (en) | 2007-01-29 | 2010-01-21 | Hiroshi Imoto | Pyrazole compound |
| MX2009008103A (es) | 2007-02-09 | 2009-08-18 | Takeda Pharmaceutical | Compuestos anulares fusionados como agonistas parciales de prar-gamma. |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| EP2149550A4 (en) | 2007-04-27 | 2010-08-11 | Takeda Pharmaceutical | NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND |
| US20110301155A1 (en) | 2007-06-19 | 2011-12-08 | Tsuneo Yasuma | Indazole compounds for activating glucokinase |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| US20100292292A1 (en) | 2007-09-13 | 2010-11-18 | Link Medicine Corporation | Treatment of Neurodegenerative Diseases Using Indatraline Analogs |
| EP2247600A4 (en) | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) |
| AR072249A1 (es) | 2008-04-09 | 2010-08-18 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de acido graso. usos. metodos. |
| CA2724774C (en) | 2008-05-28 | 2013-06-25 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CN104945500B (zh) | 2008-06-17 | 2019-07-09 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
| JP4825322B1 (ja) | 2008-08-28 | 2011-11-30 | ファイザー・インク | ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体 |
| US8735391B2 (en) | 2008-09-26 | 2014-05-27 | University Of Kansas | Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| US8575166B2 (en) | 2009-02-05 | 2013-11-05 | Merck Sharp & Dohme Corp. | Phthalazine-containing antidiabetic compounds |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| AP3179A (en) | 2009-03-11 | 2015-03-31 | Pfizer | Benzofuranyl derivatives used as glucokinase inhibitors |
| US20120095028A1 (en) | 2009-03-20 | 2012-04-19 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759891A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| BRPI1014636A2 (pt) | 2009-06-05 | 2016-04-05 | Pfizer | moduladores de gpr 119 |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| US20120021979A1 (en) | 2010-06-24 | 2012-01-26 | Vanderbilt University | GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| HUE031616T2 (hu) | 2010-09-30 | 2017-07-28 | Pfizer | N1-pirazol-spiroketon acetil-koenzim-A karboxiláz inhibítorok |
| WO2012065065A1 (en) | 2010-11-12 | 2012-05-18 | Follica, Inc. | Methods and compositions for modulating hair growth, wound healing and scar revision |
| JP5805982B2 (ja) | 2011-04-20 | 2015-11-10 | ユニチカ株式会社 | ポリアリレート樹脂フィルムおよび気体分離膜 |
| JP5687120B2 (ja) | 2011-04-20 | 2015-03-18 | ユニチカ株式会社 | ポリアリレート樹脂 |
| WO2013037690A1 (en) | 2011-09-06 | 2013-03-21 | Novo Nordisk A/S | Glp-1 derivatives |
| KR101401705B1 (ko) | 2012-01-31 | 2014-06-27 | 울산대학교 산학협력단 | 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법 |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| US20150272939A1 (en) | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| EP2953681B1 (en) * | 2013-02-06 | 2017-03-15 | Boehringer Ingelheim International GmbH | New indanyloxydihydrobenzofuranylacetic acids |
| CA2913791A1 (en) | 2013-06-11 | 2014-12-18 | Receptos, Inc. | Novel glp-1 receptor modulators |
| CN103421006B (zh) | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用 |
| EP2857550A1 (en) | 2013-10-02 | 2015-04-08 | Basf Se | Amine precursors for depositing graphene |
| MX382502B (es) | 2014-07-25 | 2025-03-13 | Receptos Llc | Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1). |
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| CN105646459A (zh) | 2014-11-13 | 2016-06-08 | 上海和辉光电有限公司 | 一种化合物及其制备方法和应用 |
| WO2016118639A1 (en) | 2015-01-20 | 2016-07-28 | The Trustees Of Columbia University In The City Of New York | Small molecule oxidizers of pdi and their use |
| AU2016382393B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Triple glucagon/GLP-1/GIP receptor agonist |
| WO2017182983A1 (en) | 2016-04-22 | 2017-10-26 | Sabic Global Technologies B.V. | Methods of manufacture of 2-aryl-3,3-bis(hydroxyaryl)phthalimidines |
| WO2017182986A1 (en) | 2016-04-22 | 2017-10-26 | Sabic Global Technologies B.V. | Methods of manufacture of 2-aryl-3,3-bis(hydroxyaryl)phthalimidines |
| WO2017182984A1 (en) | 2016-04-22 | 2017-10-26 | Sabic Global Technologies B.V. | Methods of manufacture of 2-aryl-3,3-bis (4-hydroxyaryl) phthalimidines, and polymers derived therefrom |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CU24573B1 (es) | 2016-12-16 | 2022-01-13 | Pfizer | Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas |
| IL293783B2 (en) | 2017-03-31 | 2024-01-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| JP7254082B2 (ja) | 2017-12-22 | 2023-04-07 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲ阻害剤としてのジアリール置換６，５－縮合環化合物 |
| AR114237A1 (es) | 2018-02-01 | 2020-08-05 | Japan Tobacco Inc | Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico |
| KR20200121823A (ko) | 2018-02-16 | 2020-10-26 | 유씨비 바이오파마 에스알엘 | 약학적 6,5 헤테로비시클릭 고리 유도체 |
| JP2021514982A (ja) | 2018-02-28 | 2021-06-17 | ノバルティス アーゲー | インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用 |
| US20190284341A1 (en) | 2018-03-14 | 2019-09-19 | Sabic Global Technologies B.V. | 3-oxo-2-alkylisoindoline diphthalonitrile monomers, methods of manufacture, thermosetting compositions comprising the same, and uses thereof |
| US20190284340A1 (en) | 2018-03-14 | 2019-09-19 | SABIC Global Technologies B.V | 3-oxo-2-arylisoindoline diphthalonitrile monomers, methods of manufacture, thermosetting compositions comprising the same, and uses thereof |
| AR114464A1 (es) * | 2018-04-02 | 2020-09-09 | Chemocentryx Inc | PROFÁRMACOS DE ANTAGONISTAS DE C5aR BICÍCLICOS FUSIONADOS |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| SG11202011704XA (en) | 2018-06-15 | 2020-12-30 | Pfizer | Glp-1 receptor agonists and uses thereof |
| US20220388953A1 (en) | 2018-06-27 | 2022-12-08 | The Hong Kong Polytechnic University | Compounds with antimicrobial activity |
| CN112673522B (zh) | 2018-08-02 | 2022-11-01 | 上海诺基亚贝尔股份有限公司 | 天线和无线通信设备 |
| CA3110601C (en) | 2018-08-31 | 2023-09-05 | Pfizer Inc. | Combinations for treatment of nash/nafld and related diseases |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| CN111217796B (zh) | 2018-11-26 | 2021-12-14 | 上海亚舸生物科技有限公司 | 一类螺环-二吡咯甲烷/二吡咯甲川化合物及其制备方法和应用 |
| CN111217842B (zh) | 2018-11-26 | 2023-01-31 | 上海亚舸生物科技有限公司 | 一类螺环-二吡咯甲烷硼配合物/二吡咯甲川硼配合物及其制备方法和应用 |
| CA3121620A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
| WO2020135513A1 (zh) | 2018-12-25 | 2020-07-02 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物 |
| WO2020163236A1 (en) | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Treating long qt syndrome |
| CU20210083A7 (es) | 2019-04-12 | 2022-05-11 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CN110804059B (zh) | 2019-09-30 | 2024-03-12 | 郑州泰基鸿诺医药股份有限公司 | 氨基甲酸酯类化合物、药物组合物及其应用 |
| KR20220092909A (ko) | 2019-10-25 | 2022-07-04 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
| PE20221422A1 (es) | 2019-11-15 | 2022-09-20 | Ildong Pharmaceutical Co Ltd | Agonista del receptor glp-1 y uso de este |
| TW202142538A (zh) | 2020-02-07 | 2021-11-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ－１促效劑 |
| JP2023515404A (ja) | 2020-02-13 | 2023-04-13 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4143183A4 (en) | 2020-04-29 | 2024-05-15 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
-
2021
- 2021-02-05 TW TW110104566A patent/TW202142538A/zh unknown
- 2021-02-05 ES ES21751080T patent/ES2986788T3/es active Active
- 2021-02-05 MD MDE20221353T patent/MD4097099T2/ro unknown
- 2021-02-05 HR HRP20241159TT patent/HRP20241159T1/hr unknown
- 2021-02-05 IL IL295281A patent/IL295281A/en unknown
- 2021-02-05 PL PL21751080.9T patent/PL4097099T3/pl unknown
- 2021-02-05 PH PH1/2022/552056A patent/PH12022552056A1/en unknown
- 2021-02-05 LT LTEPPCT/CN2021/075488T patent/LT4097099T/lt unknown
- 2021-02-05 HU HUE21751080A patent/HUE068174T2/hu unknown
- 2021-02-05 WO PCT/CN2021/075488 patent/WO2021155841A1/en active Application Filing
- 2021-02-05 AU AU2021216324A patent/AU2021216324B2/en active Active
- 2021-02-05 EP EP24183377.1A patent/EP4458834A3/en active Pending
- 2021-02-05 MX MX2022009524A patent/MX2022009524A/es unknown
- 2021-02-05 CN CN202180013186.2A patent/CN115698003B/zh active Active
- 2021-02-05 JP JP2022548499A patent/JP2023513272A/ja active Pending
- 2021-02-05 SI SI202130181T patent/SI4097099T1/sl unknown
- 2021-02-05 CA CA3169975A patent/CA3169975A1/en active Pending
- 2021-02-05 EP EP21751080.9A patent/EP4097099B1/en active Active
- 2021-02-05 MA MA58498A patent/MA58498B1/fr unknown
- 2021-02-05 FI FIEP21751080.9T patent/FI4097099T3/fi active
- 2021-02-05 CR CR20220371A patent/CR20220371A/es unknown
- 2021-02-05 SM SM20240344T patent/SMT202400344T1/it unknown
- 2021-02-05 KR KR1020227030940A patent/KR20220156535A/ko active Pending
- 2021-02-05 PT PT217510809T patent/PT4097099T/pt unknown
- 2021-02-05 DK DK21751080.9T patent/DK4097099T3/da active
- 2021-02-05 RS RS20240939A patent/RS65877B1/sr unknown
- 2021-02-05 PE PE2022001553A patent/PE20231066A1/es unknown
-
2022
- 2022-01-07 US US17/571,351 patent/US11492365B2/en active Active
- 2022-06-29 US US17/853,755 patent/US11926643B2/en active Active
- 2022-08-04 CL CL2022002105A patent/CL2022002105A1/es unknown
- 2022-08-04 DO DO2022000158A patent/DOP2022000158A/es unknown
- 2022-08-04 CO CONC2022/0011065A patent/CO2022011065A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231066A1 (es) | Agonistas heterociclicos de glp-1 | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR045931A1 (es) | Derivados de piperazina | |
| AR065719A1 (es) | Imidazo y triazolopirimidinas, un procedimiento para su preparacion y su uso en la elaboracion de un medicamento para el tratamiento de trastornos hematologicos. | |
| AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
| AR063458A1 (es) | Derivados de piridina inhibidores de 11beta hsd1 | |
| RU2021139070A (ru) | Ингибиторы ERBB/BTK | |
| ES2578302T3 (es) | Compuestos de 5,6-dihidro-1H-piridin-2-ona | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| RU2008116844A (ru) | Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4 | |
| AR047339A1 (es) | Derivados de difenilazetidona.proceso de obtencion. | |
| ES2080815T3 (es) | Derivados de la 1-naftil-piperacina, sus procedimientos de preparacion y composiciones farmaceuticas que los contienen. | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| PE20220252A1 (es) | Compuestos de pirrol | |
| PE20241894A1 (es) | Inhibidores de parp7 | |
| AR124303A1 (es) | Inhibidores de irak4 | |
| DE3177205D1 (de) | Industrielle verbindungen anwendbar als zwischenprodukte in der herstellung von in stellung 2 substituierten 4-hydroxy 3-quinolincarboxamid-derivaten und die herstellung von diesen zwischenprodukten. | |
| AR078155A1 (es) | Derivados de benzodiazepinas, composiciones farmaceuticas y sus usos |